Adult Immunization

MASLD/MASH

Hepatitis

Hepatology

Pediatric Immunization

Colorectal Cancer

Renal Cancer

Lung Cancer

Melanoma

Skin cancer

Prostate Cancer

Breast Cancer

Cervical Cancer

Screening

PTSD

Psychosis

Panic Disorder  

Anxiety

Eating Disorders

Depression

Substance-related Disorders

ADHD

Psychiatry 

Food Allergies

Anaphylaxis

Seasonal Allergies

Allergy

Osteoporosis

Menopause

Pregnancy and Birth

Women's Health

Heart Failure

Atrial Fibrillation

Lipid disorders

Cardiovascular Disease

Hypertension

Cardiology

Child/Adolescent

Pediatrics

Psoriasis

Rosacea

Atopic Dermatitis

Dermatology

Adrenal Disorders

Thyroid Disorders 

Diabetes

Diabetes Type 2

Endocrinology 

Fibromyalgia

Pain Management

GERD

C Difficile Infection

Celiac disease

Irritable Bowel Syndrome 

Inflammatory Bowel Disease

Gastroenterology

Geriatrics

C difficile

Coronavirus

Hepatitis C

Cold, Cough, and Flu

Immunization

Influenza

HIV AIDS

Pneumonia

Sexually transmitted infections

Infectious Disease

Obesity Medicine

Psoriatic arthritis

Lupus

Rheumatoid Arthritis

Osteoarthritis

Gout

Rheumatology

Oncology

Chronic Kidney Disease

Nephrology

Dementia

Epilepsy

Cerebrovascular Diseases

Headache and Migraine

Parkinson Disease

Alzheimer Disease/Dementia

Stroke

Mental Health

Headache

Migraine

Nervous System Diseases

Sleep Disorders

Neurology

Pulmonary hypertension

Interstitial lung disease

Asthma

Cystic Fibrosis

COPD

Respiratory Diseases

Pulmonology

News

All News

Office Procedures

Practice Management

Media

Around the Practice

Between the Lines

ConsultantLive

Expert Interviews

Frontline Insights

Institutional Insights

Medical World News

Podcasts

Primary View

Provider Toolkits

Readout360

Conferences

Conference Coverage

Conference Listing

Resources

Image IQ

Interactive Posters

Polls

Product Profile

Publications

Quizzes

Subscribe

CE/CME

About Us

Advertise

Contact Us

Editorial Board

Terms and Conditions

Privacy

Do Not Sell My Information

Patient Care Online

Facebook

LinkedIn

Clinical Focus

Allergy & Immunology

Endocrinology

Men’s Health

Psychiatry

Women’s Health

Business Focus

Billing and Collections

Career Planning

Coding and Documentation

Concierge Medicine

Cybersecurity

EHRs

Investing

Patient Relations

Personal Finance

Remote Patient Monitoring

Staffing

Technology

Telehealth

Value-based Care

Spotlight

VMS and Menopause

T1D: Paving the Path to Prevention

Adult Immunization Center

Dermatology Hot Topics

1rem

Clinical Topics

Topics

, Shagun Bindlish, MD, and Peminda K. Cabandugama, MD, discuss obesity and type 2 diabetes (T2D), including the most significant complications associated with these conditions that a primary care clinician is likely to encounter, how to best treat patients with obesity and T2D, and their suggestions to primary care clinicians on managing this patient population.

Dr Bindlish is a board member of the American Diabetes Association and medical director at One Medical in Dublin, California. 

Dr Cabandugama is the director of Digital Obesity at the Cleveland Clinic and a member of the Obesity Medicine Association.

 podcast features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today. 

 to subscribe on your favorite streaming service.

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Obesity & Type 2 Diabetes: An Expert Discussion

The Primary Viewpoints podcast features informative conversations with health care experts, opinion leaders, and practicing physicians, about what impacts primary care medicine today.

In episode 17, Dr Hiddo Heerspink, joins us to discuss findings he recently presented at the American Diabetes Association 2022 Scientific Sessions from a 

 he led of the SURPASS-4 clinical trial of tirzepatide that looked for the first time at the effects of the novel GLP-1 receptor agonist on kidney function in patients with type 2 diabetes.

Hiddo Heerspink, PhD, PharmD, is professor of clinical trials and personalized medicine and a clinical pharmacologist/trialist in the department of clinical pharmacy and pharmacology at the University Medical Center Groningen in Groningen, Netherlands; he is also Codirector of the Better Treatments Program at the George Institute for Global Health in Newtown, Australia.

 to subscribe to the Primary Viewpoints podcast. Be sure to leave a rating and review for the show. Thanks for listening!

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD. 

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

is a 49-year-old man with type 2 diabetes mellitus diagnosed 18 months ago. Treatment with metformin, 2500 mg/d, was started. His HbA1c was 8.6 initially: it’s now 7.6. His BMI decreased from 35 to 32 with lifestyle changes. Should I be any more aggressive with him or is the current A1C goal adequate?

 Does Mr Jones have any microvascular or macrovascular complications of diabetes?

He has no evidence of eye disease, renal disease or neuropathy, or cardiovascular events.

 Is he active and has he the resources to provide self-care?

 He plays tennis 4 or 5 times a week. He has good insurance coverage, has a supportive family, and has learned a lot about his diabetes since his diagnosis.

With no evidence of complications, a good support system, adequate insurance, capacity to self-manage, and recent onset of diabetes, I would be more aggressive with him. I would try to get his HbA1c as close to 6 as possible.

The UKPDS trial with patients who had recent-onset diabetes demonstrated a decrease in both microvascular and macrovascular complications with more aggressive early management. More recent trials, such as the ACCORD,

 demonstrated effectiveness and safety for a lower A1c in younger patients with no microvascular and macrovascular complications and diabetes of less than 10 to 15 years’ duration. Safety is important with aggressive treatment, so I would choose medications carefully and monitor his progress with frequent follow-up and good self-management.

 I would have used 2 medications initially because of the A1c >8. One oral agent usually will reduce the A1c about 1%. I’d add another oral agent or a GLP-1 receptor agonist. Adding a sulfonylurea such as glipizide or a glitizone such as pioglitazone will provide an additional decrease of 1% but both can produce weight gain, and hypoglycemia is a problem with the sulfonylurea.

A DPP4 inhibitor such as sitagliptin or saxtagliptin will produce about a 0.5% reduction in A1c and is weight-neutral. A GLP-1 receptor agonist will provide about a 1% drop in A1c and weight loss but must be injected.

If cost is an issue, a sulfonylurea is least expensive. Since the patient has good insurance coverage and his BMI is 32, I would opt for a GLP-1 receptor agonist such as exenatide (bid or once weekly) or liraglutide.

1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. 

http://www.nejm.org/doi/pdf/10.1056/NEJMoa0802743


2. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. 

http://www.nejm.org/doi/full/10.1056/NEJMoa0808431


3. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. 

http://www.nejm.org/doi/full/10.1056/NEJMoa0802987

The patient, an active 49-year-old man, had an HbA1c of 8.6 after diabetes was first diagnosed. It’s now 7.6 with metformin and lifestyle measures. Is the current A1c goal adequate, or should you treat more aggressively?

Man With Newly Diagnosed Type 2 Diabetes: What HbA1c Goal-And How to Get There?

70-Year-old Mrs Smith has a 7-year history of type 2 diabetes. Her medications include glipizide, 2.5 mg a day, and lisinopril, 10 mg a day. She weighs 175 pounds and her BMI is 30. Her HbA1c is 7.5 and her blood pressure 130/80. Recently she has experienced 2 episodes of dizziness and her blood sugars were 50 and 55. 

 I was surprised that her blood sugars were so low with an HbA1c of 7.5. Does that surprise you?

Hypoglycemia in type 2 diabetes patients can be the result of insulin or sulfonylureas.

Challenging Case: A Patient With Hypoglycemia and High HbA1c

Diabetes

Latest News